

**University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
May 13, 2025**

Members attending the meeting: Bieniek, Kevin; Burgin, Tiffani; Chatterjee, Bandana; Chen, Ching-Kang Jason; Dallas, Steven; Elliott, James; Gould, Georgianna; Ginsburg, Brett; Martinez-Sobrido, Luis; Mishra, Bibhuti; Paukert, Martin; Prewit, Egle; Salamango, Daniel; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Charlton, Michael - voting)

Guests Present: Melendez, Griselda; Barlett, Emily; Vasquez, Rebecca; Colby, Angelique.

Absent members: Charlton, Michael; Gauduin, Marie Claire; Ko, Jisook; Shiio, Yuzuru.

1. Panel Chair Announcement

The meeting was called to order at 11:00 a.m. by the IBC Chair, Dr. Yan Xiang. A quorum was established.

2. Confidentiality of Panel Proceedings and Conflict of Interest

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. Approval of minutes from the previous meeting

The Committee approved the minutes as written from the April 15, 2025, IBC meeting.

Approved (17 voted to approve, 0 opposed, 0 abstained)

4. Review of Approved Protocols- The spreadsheet of approved protocols will be sent out for review in August 2025.

5. Old Business – Pending IBC approval- Harris (0000019371), as of 4/15/2025; emails were sent. They have requested additional time to finalize the clarifications.

6. Educational Items – None

7. Occupational Medicine- None

8. Other –

9. Review of EHS Assistant-

10. Meeting Reminder

The next meeting will be held on June 10, 2025.

Protocols for Review

11. Presentation, Discussion, and Voting on an Initial Protocol:

Protocol ID: 0000019301

Principal Investigator: Thi, Meilinh; Medicine-Pulmonary Disease

Review Type: Full Committee Review

Form Type: Initial

Approved (17 voted to approve, 0 opposed, 0 abstained)

Initial application to work with Human blood, human urine, and vector (ARCT-032) at BSL-2 containment.
Protocol does not include the use of recombinant DNA.

This protocol was approved with clarification.

1. The committee members requested additional information on the protocol.

NIH Guidelines:

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Administration of recombinant or synthetic nucleic acid molecules into humans (e.g. Gene Transfer Protocol) III-C

12. Presentation, Discussion, and Voting on an Amendment Protocol:

Protocol ID: 0000019505

Principal Investigator: Ivanov, Dmitri; Biochemistry & Structural Biology

Review Type: Full Review

Form Type: Amendment

Approved (17 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with SF9 insect cell lines and vector (pOET5) at BSL-1 containment.
Protocol does include the use of recombinant DNA.

This protocol was approved with clarification.

1. The committee members requested additional information on the gene expression.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

13. Presentation, Discussion, and Voting on a Renewal Protocol:**Protocol ID:** 0000019476**Principal Investigator:** Blanco, Cynthia; Pediatrics-Neonatology**Review Type:** Full Review**Form Type:** Renewal**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with human stem cells at BSL-2 containment.

In vivo:

Work with human stem cells in mice at ABSL-2 containment.

IACUC# 20140047AP

Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

*NIH Guidelines:**Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1**Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4***14. Presentation, Discussion, and Voting on an Amendment Protocol:****Protocol ID:** 0000019472**Principal Investigator:** Koronowski, Kevin; Biochemistry & Structural Biology**Review Type:** Full Review**Form Type:** Amendment**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Amendment application, to work with NIH-3T3 cell line and lentiviral vector (pLV-Per-NanoLuc) at BSL-2 containment.

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

*NIH Guidelines:**Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1**Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1**Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1**Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F**Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4**Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

15. Presentation, Discussion, and Voting on a Renewal Protocol:**Protocol ID:** 0000019517**Principal Investigator:** Zhang, Nu; Microbiology, Immunology & Molecular Genetics**Review Type:** Full Review**Form Type:** Renewal**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with Vaccinia virus (MVA), *Listeria monocytogenes*, Lymphocytic choriomeningitis virus, Vesicular Stomatitis virus, Ecotropic retrovirus, human cell lines (293, Vero), lentivirus vector (LentCRISPrV2) at BSL-2 containment. Work with *E. coli*, animal cell lines (B16, TRAMP, MEER mouse tumor, MC38, c-MYC induced HCC, c-MET induced HCC, Hep53.4) and Poly I:C +Antigen peptide at BSL-1 containment.

In vivo:

Work with B16, TRAMP, MEER mouse tumor, MC38, c-MYC induced HCC, c-MET induced HCC, Hep53.4 and Poly I:C +Antigen peptide in knock-out and transgenic mice at ABSL-1 containment.

IACUC# 150014X, 20180053AR

Work with Vaccinia virus (MVA), *Listeria monocytogenes*, Lymphocytic choriomeningitis virus, Vesicular Stomatitis virus and human cell line 293T in knock-out and transgenic mice at ABSL-2 containment.

IACUC# 150014X, 20180053AR

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

*NIH Guidelines:**Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1**Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1**Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1**Cloning and vector construction in bacteria and yeasts. III-E, III-F**Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F**Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4**Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3**Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4***16. Presentation, Discussion, and Voting on an Amendment Protocol:****Protocol ID:** 0000019510**Principal Investigator:** Rao, Manjeet; Greehey CCRI**Review Type:** Full Review**Form Type:** Amendment**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with human cell lines (Panc1, Panco2, Mia PaCa-2, OVCAR3, SKOV-3,

143B, MG63, U2OS, KPC, OVCAR8, ID8, K7M2, F420) at BSL-2 containment.

In vivo:

Work with Pancreatic cell lines (Panc1, Panco2, Mia PaCa-2, KPC), Ovarian cell lines (OVCAR3, OVCAR8, SKOV-3, ID8) and human cell lines (K7M2, F420, MG63, U2OS) in mice at ABSL-2.

IACUC# IPROTO202500000043

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1


Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4

Adjourn: The meeting adjourned at 12:17 P.M.



Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio



Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam